LGD-4033 is a selective androgen receptor modulator a novel non-steroidal, oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity, class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testos-terone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
Function & Application:
The subjects showed a sustained increase in serum concentration; in addition, the nitrogen wasting was reversed, showing great potential for treatment of conditions involving muscle wasting, muscle building. A study done for the treatment of osteoporosis and bone mineral density showed some increase in bone density, so there is a true impact on bone mineral density. This can help with injury recovery during your cycle.